Abstract
Overcoming EGFR‐TKI resistant which has the initial enthusiasm over substantial clinical responses is a formidable challenge on nowadays. In this study, we showed that cholesterol level in lipid rafts in gefitinib resistant non‐small cell lung cancer (NSCLC) cell lines was remarkably higher than gefitinib sensitive cell line, and depletion of cholesterol increased gefitinib sensitivity. Furthermore, cholesterol‐depleted enhanced gefitinib inhibit phosphorylation of EGFR, Akt‐1, MEK1/2, and ERK1/2 and these were reversed in cholesterol add‐back experiments. Gefitinib resistant cell lines showed high affinity of gefitinib and EGFR when cholesterol was depleted. Therefore, targeting cholesterol combined with EGFR‐TKI is potentially a novel therapeutic strategy for gefitinib resistant treatment.
Funding Information
  • Innovative Project of Postgraduate in Jiangsu Province (KYLX16_1201)

This publication has 39 references indexed in Scilit: